Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Tuesday that its first quarter 2018 revenues rose 22 percent year over year

For the three months ended March 31, the genomic testing firm reported total revenues of $20.0, compared to $16.4 million in Q1 2017, beating analysts' average estimate of $18.0 million.

"We had a great quarter in which we beat revenue and genomic test volume growth expectations and generated strong momentum across our business," Bonnie Anderson, chairman and CEO of Veracyte, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.